ADCC-Enhanced Biobetters

ADCC-enhanced biobetters represent a cutting-edge advancement in therapeutic antibody development. By improving Antibody-Dependent Cellular Cytotoxicity (ADCC), these biobetters offer superior efficacy in targeting and eliminating diseased cells, such as cancer cells, compared to traditional monoclonal antibodies. This enhancement is achieved through modifications that increase the binding affinity of antibodies to immune effector cells, thereby amplifying the body's natural immune response. ADCC-enhanced biobetters hold great promise in the treatment of various cancers and autoimmune diseases, paving the way for more effective and targeted therapies that maximize patient outcomes.